head uk2

Chitosan nanoparticles - potential drug delivery systems for COVID-19 drugs

Chitosan nanoparticles can deliver drugs to their specific target site and release them over a long period. In current corona crisis, chitosan nanoparticles could be one way to release potential COVID-19 drugs specifically in the lungs of affected patients. A potential drug delivery system for the treatment of SARS-CoV-2 infected persons is Novochizol™, consisting of chitosan-based nanoparticles.

Tags: nanoparticles, Corona

The company Bioavanta-Bosti developed the production of Novochizol™. A two-step activation of chitosan and the addition of a potential Covid-19 active ingredient could produce nanoparticles that are ideal for intra-pulmonary drug release. Therefore the active substances could be released locally, thus inhibiting the inflammatory reaction and preventing damage to lung tissue. In current studies of Novochizol™ aerosols with other drugs (e.g. Losartan), the manufacturers have already been able to determine the successful drug release from therapeutic doses over 25 minutes to 3 hours. Bioavanta-Bosti is currently looking for partners in developing effective therapeutic solutions for the treatment of COVID-19 patients.

More information can be found here:

Congress and fairs

Meet us in person 2022:

  • EUCHIS, 2022
  • CPHI 2022
  • Medica 2022
  • Asia Pacific Chitin and Chitosan Symposium, 2022, South Korea

To arrange an appointment please contact Katja Richter via sales(at)


  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.